Ubs Group Ag Provention Bio, Inc. Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 12, 2023
BUY
$6.7 - $24.21 $1.85 Million - $6.7 Million
276,789 Added 639.99%
320,038 $7.71 Million
Q4 2022

Feb 08, 2023
BUY
$4.52 - $10.57 $51,062 - $119,409
11,297 Added 35.36%
43,249 $457,000
Q3 2022

Nov 10, 2022
SELL
$3.43 - $5.62 $1,118 - $1,832
-326 Reduced 1.01%
31,952 $144,000
Q2 2022

Aug 10, 2022
SELL
$3.65 - $7.3 $12,191 - $24,382
-3,340 Reduced 9.38%
32,278 $129,000
Q1 2022

May 16, 2022
SELL
$3.4 - $7.88 $7,677 - $17,793
-2,258 Reduced 5.96%
35,618 $261,000
Q4 2021

Feb 14, 2022
BUY
$5.59 - $7.39 $19,022 - $25,148
3,403 Added 9.87%
37,876 $213,000
Q3 2021

Nov 15, 2021
SELL
$5.66 - $8.33 $14,461 - $21,283
-2,555 Reduced 6.9%
34,473 $221,000
Q2 2021

Aug 13, 2021
SELL
$6.71 - $11.04 $60,155 - $98,973
-8,965 Reduced 19.49%
37,028 $312,000
Q1 2021

May 12, 2021
BUY
$10.12 - $19.45 $111,289 - $213,891
10,997 Added 31.42%
45,993 $483,000
Q4 2020

Feb 11, 2021
SELL
$11.79 - $18.94 $94,390 - $151,633
-8,006 Reduced 18.62%
34,996 $593,000
Q3 2020

Nov 12, 2020
SELL
$10.34 - $15.2 $39,198 - $57,623
-3,791 Reduced 8.1%
43,002 $551,000
Q2 2020

Jul 31, 2020
BUY
$7.81 - $17.0 $163,681 - $356,286
20,958 Added 81.12%
46,793 $660,000
Q1 2020

May 01, 2020
BUY
$5.42 - $17.75 $27,078 - $88,679
4,996 Added 23.97%
25,835 $238,000
Q4 2019

Feb 14, 2020
BUY
$5.84 - $14.9 $49,464 - $126,203
8,470 Added 68.48%
20,839 $311,000
Q3 2019

Nov 14, 2019
BUY
$6.83 - $13.0 $84,480 - $160,797
12,369 New
12,369 $84,000
Q4 2018

Feb 14, 2019
SELL
$1.73 - $4.0 $4,930 - $11,400
-2,850 Closed
0 $0
Q3 2018

Nov 14, 2018
BUY
$3.4 - $4.81 $9,690 - $13,708
2,850 New
2,850 $11,000

Others Institutions Holding PRVB

# of Institutions
1
Shares Held
170K
Call Options Held
0
Put Options Held
0
View Full List

About Provention Bio, Inc.

PRVB Quotes by TradingView
  • Ticker PRVB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 81,549,904
  • Description
  • Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...
More about PRVB
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email